RT Journal Article
SR Electronic
T1 Use of Rituximab for the Treatment of Antineutrophil Cytoplasm Antibody–associated Vasculitis in Canada, 2010–2020
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.210537
DO 10.3899/jrheum.210537
A1 Arielle Mendel
A1 Christian Pagnoux
YR 2021
UL http://www.jrheum.org/content/early/2021/08/26/jrheum.210537.abstract
AB Rituximab (RTX) is the only biologic approved to date for the treatment of antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV).1,2,3 The Canadian Vasculitis Research Network (CanVasc) has recommended RTX as first-line therapy for remission induction,4 and recently, as the preferred maintenance agent in severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).5